Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

A. Ceriello, E. Standl, D. Catrinoiu, B. Itzhak, NM. Lalic, D. Rahelic, O. Schnell, J. Škrha, P. Valensi, Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group,

. 2020 ; 43 (7) : 1427-1432. [pub] 20200514

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024918

People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024918
003      
CZ-PrNML
005      
20201222154941.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2337/dc20-0941 $2 doi
035    __
$a (PubMed)32409501
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ceriello, Antonio $u IRCCS MultiMedica, Milan, Italy antonio.ceriello@hotmail.it.
245    10
$a Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era / $c A. Ceriello, E. Standl, D. Catrinoiu, B. Itzhak, NM. Lalic, D. Rahelic, O. Schnell, J. Škrha, P. Valensi, Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group,
520    9_
$a People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    12
$a Betacoronavirus $7 D000073640
650    _2
$a krevní glukóza $7 D001786
650    _2
$a selfmonitoring glykemie $7 D015190
650    _2
$a kardiovaskulární nemoci $x epidemiologie $x terapie $7 D002318
650    _2
$a komorbidita $7 D015897
650    _2
$a Coronavirus $x účinky léků $7 D017934
650    _2
$a koronavirové infekce $x farmakoterapie $x epidemiologie $7 D018352
650    _2
$a diabetes mellitus $x farmakoterapie $x epidemiologie $7 D003920
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $7 D058873
650    _2
$a virová pneumonie $x epidemiologie $7 D011024
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Standl, Eberhard $u Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.
700    1_
$a Catrinoiu, Doina $u Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.
700    1_
$a Itzhak, Baruch $u Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.
700    1_
$a Lalic, Nebojsa M $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Rahelic, Dario $u Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia. University of Zagreb School of Medicine, Zagreb, Croatia. University of Osijek School of Medicine, Osijek, Croatia.
700    1_
$a Schnell, Oliver $u Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.
700    1_
$a Škrha, Jan $u Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Valensi, Paul
710    2_
$a Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
773    0_
$w MED00001380 $t Diabetes care $x 1935-5548 $g Roč. 43, č. 7 (2020), s. 1427-1432
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32409501 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154937 $b ABA008
999    __
$a ok $b bmc $g 1599063 $s 1115604
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 43 $c 7 $d 1427-1432 $e 20200514 $i 1935-5548 $m Diabetes care $n Diabetes Care $x MED00001380
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace